134 related articles for article (PubMed ID: 38569859)
1. [Successful bridging therapy with alectinib prior to allogeneic stem cell transplantation for refractory ALK-positive anaplastic large cell lymphoma].
Kono A; Tanaka K; Shimada T; Bando K; Takahata A; Koi S; Yamamoto M; Mori T; Toyota S
Rinsho Ketsueki; 2024; 65(3):158-163. PubMed ID: 38569859
[TBL] [Abstract][Full Text] [Related]
2. Long-term remission of primary refractory ALK-positive anaplastic large cell lymphoma after allogeneic hematopoietic stem cell transplantation.
Miyazaki M; Ichikawa S; Onishi Y; Fukuhara N; Furukawa E; Onodera K; Yokoyama H; Ichinohasama R; Harigae H
J Clin Exp Hematop; 2022 Sep; 62(3):164-168. PubMed ID: 35732409
[TBL] [Abstract][Full Text] [Related]
3. Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors: A case report.
Saito S; Tashiro H; Sumiyoshi R; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N
Medicine (Baltimore); 2021 Apr; 100(15):e25576. PubMed ID: 33847688
[TBL] [Abstract][Full Text] [Related]
4. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.
Fukano R; Mori T; Sekimizu M; Choi I; Kada A; Saito AM; Asada R; Takeuchi K; Terauchi T; Tateishi U; Horibe K; Nagai H
Cancer Sci; 2020 Dec; 111(12):4540-4547. PubMed ID: 33010107
[TBL] [Abstract][Full Text] [Related]
5. [Outcomes of 33 patients with anaplastic large cell lymphoma treated after hematopoietic stem cell transplantation].
Lu N; Li XF; Dong YJ; Wang YN; Fu XR; Wu YM; Li YH; Wang MH; Li NN; Ren HY; Wang Z; Zhang MZ; Wu XX; Hu LD; Liu Y; Huang WR
Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):117-122. PubMed ID: 32135627
[No Abstract] [Full Text] [Related]
6. Successful treatment of relapsed anaplastic large cell lymphoma with vinblastine monotherapy and allo-HSCT with reduced intensity conditioning regimen.
Miyagaki S; Imamura T; Okumura Y; Ito I; Fujiki A; Osone S; Ishida H; Hosoi H
Pediatr Int; 2015 Aug; 57(4):791-4. PubMed ID: 25847601
[TBL] [Abstract][Full Text] [Related]
7. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
[No Abstract] [Full Text] [Related]
8. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report.
Woessmann W; Peters C; Lenhard M; Burkhardt B; Sykora KW; Dilloo D; Kremens B; Lang P; Führer M; Kühne T; Parwaresch R; Ebell W; Reiter A
Br J Haematol; 2006 Apr; 133(2):176-82. PubMed ID: 16611309
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia].
Tao SD; Song LX; Deng Y; Chen Y; Zhang X; Ding BH; Wang CL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):677-684. PubMed ID: 37356926
[TBL] [Abstract][Full Text] [Related]
10. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.
Liu W; Wu J; Ming X; Zhang Q; Zhou D; Zheng R; Zhou M; Shang Z; Chen L; Zhu X; Xiao Y
Front Immunol; 2024; 15():1346001. PubMed ID: 38375471
[TBL] [Abstract][Full Text] [Related]
11. Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation.
Koh KN; Im HJ; Suh JK; Lee SW; Choi ES; Seo JJ
Pediatr Blood Cancer; 2015 Jun; 62(6):1063-5. PubMed ID: 25641881
[TBL] [Abstract][Full Text] [Related]
12. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
Mediwake H; Morris K; Curley C; Butler J; Kennedy G
Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
[TBL] [Abstract][Full Text] [Related]
13. [Successful allogeneic bone marrow transplantation with reduced intensity conditioning regimen for a pediatric relapsed ALK positive anaplastic large cell lymphoma].
Hayase T; Niijima H; Tanaka D; Wada S; Kawahara Y; Oh Y; Morimoto A
Rinsho Ketsueki; 2016 Jul; 57(7):859-63. PubMed ID: 27498729
[TBL] [Abstract][Full Text] [Related]
14. Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin.
Nakai R; Fukuhara S; Maeshima AM; Kim SW; Ito Y; Hatta S; Suzuki T; Yuda S; Makita S; Munakata W; Suzuki T; Maruyama D; Izutsu K
Clin Case Rep; 2019 Dec; 7(12):2500-2504. PubMed ID: 31893088
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma.
Ishizawa K; Yanai T
Adv Ther; 2019 Oct; 36(10):2679-2696. PubMed ID: 31392578
[TBL] [Abstract][Full Text] [Related]
16. [Spontaneous remission of relapsed skin lesions of ALK-positive anaplastic large cell lymphoma after autologous stem cell transplantation].
Yamazaki R; Koda Y; Abe R; Sakurai M; Kikuchi T; Kato J; Ouchi T; Mikami S; Mori T
Rinsho Ketsueki; 2021; 62(1):25-29. PubMed ID: 33551421
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
18. [Successful alectinib monotherapy for residual disease after brentuximab vedotin combined chemotherapy in ALK-positive anaplastic large cell lymphoma].
Sakata M; Saburi M; Kawano K; Takata H; Miyazaki Y; Nagamatsu K; Gamachi A; Ohtsuka E
Rinsho Ketsueki; 2022; 63(8):855-859. PubMed ID: 36058854
[TBL] [Abstract][Full Text] [Related]
19. Successful combination of crizotinib and hematopoietic stem cell transplantation in relapsed ALK-positive ALCL.
Sun X; Fang X; Jiang Y
Indian J Cancer; 2021; 58(1):108-111. PubMed ID: 33402581
[TBL] [Abstract][Full Text] [Related]
20. Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan.
Fukano R; Mori T; Kobayashi R; Mitsui T; Fujita N; Iwasaki F; Suzumiya J; Chin M; Goto H; Takahashi Y; Hara J; Park YD; Inoue M; Koga Y; Inagaki J; Sakamaki H; Adachi S; Kawa K; Kato K; Suzuki R
Br J Haematol; 2015 Feb; 168(4):557-63. PubMed ID: 25312752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
